What was Vidhi Specialty Food's revenue in Q4 FY26?

Vidhi Specialty Food reported revenue of ₹123 Cr in Q4 FY26, a -0.6% change year-over-year.

Did Vidhi Specialty Food management deliver on previous promises?

Scorecard data is being built as historical quarters are processed.

Vidhi Specialty Food Q4 FY26 Research Workspace: Revenue ₹123 Cr (-0.6%)

Q: What guidance did Vidhi Specialty Food management give?

Full capacity utilization in FY27: Management expects full utilization of both Dhar and RoA facilities in FY27, driven by robust demand recovery.

Revenue ₹123 Cr -0.6%

EBITDA ₹78 Cr +14.71%

PAT ₹13 Cr +20.8%

EBITDA Margin 17% +261bps

Duration 47 min

Read Time 1 min read

✓ Verified against BSE filing

2-Minute Summary

✦ AI-Generated from Full Transcript

Vidhi Specialty Food Ingredients reported FY26 revenue of ₹380 crore, marginally down from ₹382.3 crore due to global demand slowdown and tariff volatility. However, EBITDA grew 14.7% to ₹78 crore and PAT rose 20.8% to ₹49.15 crore, driven by product mix improvement and cost controls. EBITDA margin expanded 261 bps to 20.52%, with manufacturing sales margins at ~24-25%. Management guided for full capacity utilization in FY27 and expects value-added product contribution to double from 5% to 10-12%. A major capex of ₹75-85 crore is planned for new high-margin product lines, with commissioning in H2 FY28. The pharma coating range (Quote Icon) is in advanced sampling stages. Key risk: continued geopolitical disruptions in key export markets (Iran, Bangladesh, Philippines) could delay demand recovery.

Risks4 trackedTranscriptfull text

Research workspace

Focused Modules

!Risks 4 risks

Risk Intelligence

Geopolitical disruptions in key export markets

View Risks →

≡Transcript Full text

Call Transcript

Full transcript text is available on this route.

Read Transcript →

Quarter Snapshot

Value-added product contribution 5%

+0% YoY

Contribution of high-margin value-added products to total portfolio; expected to double to 10-12% in FY27.

Manufacturing sales EBITDA margin 24-25%

+300-400bps YoY

EBITDA margin on manufacturing sales (₹330 crore) is significantly higher than blended margin, indicating core strength.

US export share 19%

0% YoY

US (including Canada) accounts for 19% of exports, not 44% as some analysts assumed; management clarified no FDA ban on synthetic colors.

New product capex ₹75-85 crore

New

Capex for new high-margin product line at Dhar; expected to generate ₹125-150 crore revenue in first phase, commissioning in H2 FY28.

Fast read

Guidance and risk preview

Top guidance Full capacity utilization in FY27

Management expects full utilization of both Dhar and RoA facilities in FY27, driven by robust demand recovery.

Top risk Geopolitical disruptions in key export markets

Markets like Iran, Bangladesh, and Philippines are severely impacted by geopolitical tensions, delaying demand recovery.